Dr.
Gary Gilliland
Fred Hutchinson Cancer Center
Oncologist; Research institution administrator
Area
Biological Sciences
Specialty
Medical Sciences
Elected
2016
Gilliland discovered JAK2 mutations as drivers of myeloproliferative disorders and contributed to the development of targeted therapies for these diseases. As Senior Vice President for Global Oncology, he directed the development of pembrolizumab (anti-PD1) for treatment of metastatic melanoma. His work contributed to the paradigm of precision medicine and individualized therapy for cancer. He joined the University of Pennsylvania in 2013 as Vice Dean and Vice President for Precision Medicine and is currently President and Director of the Fred Hutchinson Cancer Research Center, where is he will continue to enhance academic-industry relations for the development of novel cancer immunotherapies.
Last Updated